Details
Stereochemistry | MIXED |
Molecular Formula | C20H37O7S.Na |
Molecular Weight | 444.558 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S([O-])(=O)=O
InChI
InChIKey=APSBXTVYXVQYAB-UHFFFAOYSA-M
InChI=1S/C20H38O7S.Na/c1-5-9-11-16(7-3)14-26-19(21)13-18(28(23,24)25)20(22)27-15-17(8-4)12-10-6-2;/h16-18H,5-15H2,1-4H3,(H,23,24,25);/q;+1/p-1
Molecular Formula | C20H37O7S |
Molecular Weight | 421.569 |
Charge | -1 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | Na |
Molecular Weight | 22.9898 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Docusate, also known as docusate salts or dioctyl sulfosuccinate, prevents/relieves dry hard stool and thus is used to treat constipation. Results usually occurs 1 to 3 days after the first dose. In North America, docusate and a stimulant laxative such as sennosides are commonly used in bowel treatment protocols associated with institutionalized elderly and oncology treatments. A paucity of evidence is available to support the use of the stool softener docusate yet it continues to be prescribed in everyday clinical practice for the aforementioned populations. While the actual cost of docusate is low, additional costs associated with its administration (i.e. nursing time) and its widespread use can be significant. Docusate is absorbed into the bloodstream and excreted via the gallbladder after undergoing extensive metabolism. The effect of docusate may not necessarily be all due to its surfactant properties. Perfusion studies suggest that docusate inhibits fluid absorption or stimulates secretion in the portion of the small intestine known as the jejunum
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Separation of gamma-globulins from porcine plasma by reversed micellar extraction. | 2001 |
|
Interactions of tryptophan and serotonin with biomembrane models: binding to reversed micellar systems of ionic and non ionic surfactants. | 2001 Jul-Aug |
|
Microstructure determination of AOT + phenol organogels utilizing small-angle X-ray scattering and atomic force microscopy. | 2001 Mar 14 |
|
Spectrophotometric investigation of the binding of vitamin E to water-containing reversed micelles. | 2002 Mar 2 |
|
Effect of di-2-ethylhexyl sodium sulfosuccinate reversed micelles on the iron-tetrasulfonatophthalocyanine-catalyzed fluorogenic oxidation reaction of L-tyrosine with hydrogen peroxide. | 2002 May |
|
Effect of reverse micelles on the Rose Bengal-sensitized photo-oxidation of 1- and 2-hydroxynaphthalenes. | 2004 |
|
Removal of ionic dyes from water by solvent extraction using reverse micelles. | 2004 Apr 15 |
|
Conformational changes of beta-lactoglobulin in sodium bis(2-ethylhexyl) sulfosuccinate reverse micelles. A fluorescence and CD study. | 2004 Feb |
|
Selective precipitation and recovery of xylanase using surfactant and organic solvent. | 2004 Jun 20 |
|
Aerosol-OT-gamma-alumina admicelles for the concentration of hydrophobic organic compounds in water. | 2004 Jun 25 |
|
Micro-Raman investigations of myelins in aerosol-OT/water system. | 2004 Jun 8 |
|
Higher order structure of proteins solubilized in AOT reverse micelles. | 2004 Nov 15 |
|
Reverse micellar aggregates: effect on ketone reduction. 2. Surfactant role. | 2004 Nov 26 |
|
Reverse micellar aggregates: effect on ketone reduction. 1. Substrate role. | 2004 Nov 26 |
|
Enhanced stabilization of aerosol-OT surfactant monolayer upon interaction with small amounts of bovine serum albumin at the air-water interface. | 2004 Oct 10 |
|
Effect of the addition of water-soluble polymers on the interfacial properties of aerosol OT vesicles. | 2004 Oct 15 |
|
Spontaneous vesicle formation and vesicle-tubular microstructure transition in aqueous solution of a poly-tailed cationic and anionic surfactants mixture. | 2004 Oct 15 |
|
Transition from micelle to vesicle in aqueous mixtures of anionic/zwitterionic surfactants studied by fluorescence, conductivity, and turbidity methods. | 2005 Apr 15 |
|
Surfactant self-assembling in gas phase: electrospray ionization- and matrix-assisted laser desorption/ionization-mass spectrometry of singly charged AOT clusters. | 2005 Dec |
|
Effect of graded hydration on the dynamics of an ion channel peptide: a fluorescence approach. | 2005 Feb |
|
Dynamics of water confined on a nanometer length scale in reverse micelles: ultrafast infrared vibrational echo spectroscopy. | 2005 Feb 11 |
|
Vibrational relaxation of azide in formamide reverse micelles. | 2005 Jul 7 |
|
Nucleation and growth characteristics of a binary low-mass organogel. | 2006 Aug 15 |
|
Lipophilic porphyrin microparticles induced by AOT reverse micelles: a fluorescence lifetime imaging study. | 2006 Jan 20 |
|
An insight into the mechanism of protein separation by colloidal gas aphrons (CGA) generated from ionic surfactants. | 2006 Nov 7 |
|
Spectrofluorimetric determination of tin in canned foods. | 2006 Oct 11 |
|
A novel composite: layered double hydroxides encapsulated in vesicles. | 2007 Dec 20 |
|
Dye-sensitized solar cells based on nanocrystalline titania electrodes made at various sintering temperatures. | 2007 Feb |
|
Iron dissolution in aqueous AOT solution. | 2007 Feb 15 |
|
The dispersion-stability diagram of boehmite nanoparticles in aqueous AOT solutions. | 2007 Feb 15 |
|
P450cam biocatalysis in surfactant-stabilized two-phase emulsions. | 2008 Apr 15 |
|
Micellization and synergistic interaction of binary surfactant mixtures based on sodium nonylphenol polyoxyethylene ether sulfate. | 2008 Feb 15 |
|
Kinetics of the photosensitized oxidation of chymotrypsin in different media. | 2008 Jan |
|
On the investigation of the bilayer functionalities of 1,2-di-oleoyl-sn-glycero-3-phosphatidylcholine (DOPC) large unilamellar vesicles using cationic hemicyanines as optical probes: a wavelength-selective fluorescence approach. | 2008 Jan 1 |
|
Design and control of patterns in reaction-diffusion systems. | 2008 Jun |
|
Physico-chemical investigation of nanostructures in liquid phases: nickel chloride ionic clusters confined in sodium bis(2-ethylhexyl) sulfosuccinate reverse micelles. | 2009 Aug 1 |
|
Characterization of multifunctional reverse micelles' interfaces using hemicyanines as molecular probes. II: Effect of the surfactant. | 2009 May 14 |
|
Complexes between high charge density cationic polyelectrolytes and anionic single- and double-tail surfactants. | 2009 May 21 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/docusate.html
Usual Adult Dose for Constipation:
Oral: 50 to 400 mg (using any of the salt forms) orally administered in 1 to 4 equally divided doses each day.
Rectal: 200 to 283 mg rectally administered as an enema once or twice. Alternative: 50 to 100 mg (docusate sodium liquid) added to a retention or flushing enema once a day.
Usual Pediatric Dose for Constipation:
Oral: less than 3 years: 10 to 40 mg (docusate sodium) orally divided in 1 to 4 doses. 3 to 6 years: 20 to 60 mg (docusate sodium) orally divided in 1 to 4 doses. 6 to 12 years: 40 to 150 mg (docusate sodium) orally divided in 1 to 4 doses. greater than 12 years: 50 to 400 mg (using any of the salt forms) orally administered in 1 to 4 equally divided doses each day.
Rectal: 3 to 18 years: 50 to 100 mg (docusate sodium liquid) added to a retention or flushing enema once a day. Alternative: 200 to 283 mg rectally administered as an enema once daily as needed for constipation.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11530185
It was evaluated the efficacy and toxicity of docusate against herpes simplex viruses (HSV). Docusate was effective in vitro against wild type and drug-resistant strains of HSV type 1 and 2 with EC(90-100) (effective concentration giving 90-100% virus yield reduction) of approximately 0.005% (w/v). The cytotoxicity profiles of docusate were time- and dose-dependent and thus associated with the frequency of use. Kinetics of inactivation examined by pre-mixing virus and drug in a time-course experiment demonstrated that docusate could reach its EC(90-100) within 30 min.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:01:22 GMT 2023
by
admin
on
Fri Dec 15 15:01:22 GMT 2023
|
Record UNII |
F05Q2T2JA0
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A06AG10
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-480
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
CFR |
21 CFR 176.170
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
WHO-VATC |
QA06AG10
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
CFR |
21 CFR 172.520
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
JECFA EVALUATION |
INS-480
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
CFR |
21 CFR 172.810
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
CFR |
21 CFR 175.320
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
WHO-VATC |
QA06AA02
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
WHO-ATC |
A06AA02
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
NCI_THESAURUS |
C29699
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.4
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
||
|
DSLD |
3169 (Number of products:31)
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
531
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
C460182
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
m4716
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | Merck Index | ||
|
23673837
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
CHEMBL1477036
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
1224802
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
577-11-7
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
C29000
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
F05Q2T2JA0
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
F05Q2T2JA0
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
71722
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | RxNorm | ||
|
941
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
DTXSID8022959
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
209-406-4
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
3065
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
133817
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
SUB06348MIG
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
DBSALT001500
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
DIOCTYL SODIUM SULFOSUCCINATE
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
760404
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY | |||
|
100000092012
Created by
admin on Fri Dec 15 15:01:22 GMT 2023 , Edited by admin on Fri Dec 15 15:01:22 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |